Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.

BACKGROUND & AIMS NAFLD is highly prevalent but only a small subset of patients develop advanced liver fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis tests and liver stiffness measurement (LSM) by FibroScan for the diagnosis of liver fibrosis and the evaluation of prognosis in NAFLD. METHODS Diagnostic accuracy was evaluated in a cross-sectional study including 452 NAFLD patients with liver biopsy (NASH-CRN fibrosis stage), LSM, and eight blood fibrosis tests (BARD, NAFLD fibrosis score, FibroMeter(NAFLD), aspartate aminotransferase to platelet ratio index (APRI), FIB4, FibroTest, Hepascore, FibroMeter(V2G)). Prognostic accuracy was evaluated in a longitudinal study including 360 NAFLD patients. RESULTS LSM and FibroMeter(V2G) were the two best-performing tests in the cross-sectional study: AUROCs for advanced fibrosis (F3/4) were, respectively, 0.831±0.019 and 0.817±0.020 (p⩽0.041 vs. other tests); rates of patients with ⩾90% negative/positive predictive values for F3/4 were 56.4% and 46.7% (p<0.001 vs. other tests); Obuchowski indexes were 0.834±0.014 and 0.798±0.016 (p⩽0.036 vs. other tests). Two fibrosis classifications were developed to precisely estimate the histological fibrosis stage from LSM or FibroMeter(V2G) results without liver biopsy (diagnostic accuracy, respectively: 80.8% vs. 77.4%, p=0.190). Kaplan-Meier curves in the longitudinal study showed that both classifications categorised NAFLD patients into subgroups with significantly different prognoses (p<0.001): the higher was the class of the fibrosis classification, the worse was the prognosis. CONCLUSIONS LSM and FibroMeter(V2G) were the most accurate of nine evaluated tests for the non-invasive diagnosis of liver fibrosis in NAFLD. LSM and FibroMeter(V2G) fibrosis classifications help physicians estimate both fibrosis stage and patient prognosis in clinical practice. LAY SUMMARY The amount of liver fibrosis is the main determinant of the liver-related prognosis in patients with non-alcoholic fatty liver disease (NAFLD). We evaluated eight blood tests and FibroScan in a cross-sectional diagnostic study and found that FibroScan and the blood test FibroMeter(V2G) were the two most accurate tests for the non-invasive evaluation of liver fibrosis in NAFLD. A longitudinal prognostic study showed these two tests initially developed for the diagnosis are also prognostic markers as they allow for the stratification of NAFLD patients in several subgroups with significantly different prognosis.

[1]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[2]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[3]  G. Sebastiani,et al.  Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis , 2015, PloS one.

[4]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[5]  A. Canbay,et al.  Extrahepatic complications of nonalcoholic fatty liver disease , 2014, Hepatology.

[6]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[7]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[8]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[9]  V. de Lédinghen,et al.  Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive , 2012, Hepatology.

[10]  D. Harnois.  Nonobese Population in a Developing Country Has a High Prevalence of Nonalcoholic Fatty Liver and Significant Liver Disease , 2010 .

[11]  I. Guha,et al.  Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease , 2006, Gut.

[12]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[13]  V. Wong,et al.  Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. , 2012, Journal of hepatology.

[14]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[15]  H. Makhlouf,et al.  Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.

[16]  G. Hunault,et al.  Reproducibility of blood tests of liver fibrosis in clinical practice. , 2008, Clinical biochemistry.

[17]  S. Bota,et al.  New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[18]  C. Aubé,et al.  Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. , 2012, Expert opinion on medical diagnostics.

[19]  F. Laine,et al.  Comparison of blood tests for liver fibrosis specific or not to NAFLD. , 2009, Journal of hepatology.

[20]  V. de Lédinghen,et al.  Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. , 2012, Journal of hepatology.

[21]  J. Kench,et al.  Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. , 2005, Clinical chemistry.

[22]  T. Poynard,et al.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.

[23]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[24]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[25]  V. de Lédinghen,et al.  An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. , 2015, Journal of hepatology.

[26]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[27]  A. Pollett,et al.  Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients , 2012, Hepatology.

[28]  S. Bertrais,et al.  Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C , 2011, BMC gastroenterology.

[29]  S. Bertrais,et al.  Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C , 2014, Alimentary pharmacology & therapeutics.

[30]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[31]  N. Afdhal,et al.  Evaluation of Liver Fibrosis: A Concise Review , 2004, American Journal of Gastroenterology.

[32]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[33]  I. Guha,et al.  Future use of the Glasgow alcoholic hepatitis score. , 2006, Gut.

[34]  S. Friedman,et al.  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer , 2014, Current opinion in oncology.

[35]  P. Bedossa,et al.  Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). , 2010, Journal of hepatology.

[36]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[37]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[38]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[39]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[40]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[41]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[42]  D. Thabut,et al.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.

[43]  P. Bejarano.  Portal Chronic Inflammation in Nonalcoholic Fatty Liver Disease (NAFLD): A Histologic Marker of Advanced NAFLD—Clinicopathologic Correlations from the Nonalcoholic Steatohepatitis Clinical Research Network , 2010 .

[44]  F. Carrat,et al.  How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.

[45]  V. Wong,et al.  Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease , 2012, The American Journal of Gastroenterology.

[46]  M. Stepanova,et al.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.